DK1360287T3 - Fremgangsmåder til modifikation af eukaryotiske celler - Google Patents

Fremgangsmåder til modifikation af eukaryotiske celler

Info

Publication number
DK1360287T3
DK1360287T3 DK02709544.7T DK02709544T DK1360287T3 DK 1360287 T3 DK1360287 T3 DK 1360287T3 DK 02709544 T DK02709544 T DK 02709544T DK 1360287 T3 DK1360287 T3 DK 1360287T3
Authority
DK
Denmark
Prior art keywords
procedures
modification
eukaryotic cells
eukaryotic
cells
Prior art date
Application number
DK02709544.7T
Other languages
English (en)
Other versions
DK1360287T4 (da
Inventor
Andrew J Murphy
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25133744&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1360287(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK1360287T3 publication Critical patent/DK1360287T3/da
Publication of DK1360287T4 publication Critical patent/DK1360287T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
DK02709544.7T 2001-02-16 2002-02-15 Fremgangsmåder til modifikation af eukaryotiske celler DK1360287T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/784,859 US6596541B2 (en) 2000-10-31 2001-02-16 Methods of modifying eukaryotic cells
PCT/US2002/004500 WO2002066630A1 (en) 2001-02-16 2002-02-15 Methods of modifying eukaryotic cells

Publications (2)

Publication Number Publication Date
DK1360287T3 true DK1360287T3 (da) 2012-10-08
DK1360287T4 DK1360287T4 (da) 2019-06-11

Family

ID=25133744

Family Applications (9)

Application Number Title Priority Date Filing Date
DK19203913.9T DK3626819T3 (da) 2001-02-16 2002-02-15 Transgen mus, som producerer hybrid-antistoffer indeholdende humane variable områder og konstante områder fra mus
DK16171561.0T DK3085780T3 (da) 2001-02-16 2002-02-15 Fremstilling af hybride antistoffer, der indeholder variable humane områder og konstante gnaverområder
DK19172361.8T DK3572508T3 (en) 2001-02-16 2002-02-15 Hybrid antibodies containing heavy chains with human vdj region and mouse heavy chain constant region and light chains with human vj region and mouse light chain constant region
DK14172437.7T DK2786657T3 (da) 2001-02-16 2002-02-15 Fremgangsmåde til fremstilling af et antistof, som omfatter en variabel human-region og en konstant gnaver-region
DK10010741.6T DK2264163T3 (da) 2001-02-16 2002-02-15 Fremgangsmåder til modifikation af eukaryotiske celler
DK02709544.7T DK1360287T4 (da) 2001-02-16 2002-02-15 Fremgangsmåder til modifikation af eukaryotiske celler
DK16171559.4T DK3085779T3 (da) 2001-02-16 2002-02-15 Fremgangsmåde til modifikation af eukaryotiske celler
DK14172420.3T DK2787075T3 (da) 2001-02-16 2002-02-15 Gnaver, der er i stand til at producere hybride antistoffer indeholdende variable områder fra mennesker og konstante områder fra gnavere
DK14163642.3T DK2767588T3 (da) 2001-02-16 2002-02-15 Anvendelse af mus, der producerer hybride antistoffer indeholdende humane variable områder og konstante områder fra musen som en kilde til DNA, der koder for et humant, variabelt område af antistoffet

Family Applications Before (5)

Application Number Title Priority Date Filing Date
DK19203913.9T DK3626819T3 (da) 2001-02-16 2002-02-15 Transgen mus, som producerer hybrid-antistoffer indeholdende humane variable områder og konstante områder fra mus
DK16171561.0T DK3085780T3 (da) 2001-02-16 2002-02-15 Fremstilling af hybride antistoffer, der indeholder variable humane områder og konstante gnaverområder
DK19172361.8T DK3572508T3 (en) 2001-02-16 2002-02-15 Hybrid antibodies containing heavy chains with human vdj region and mouse heavy chain constant region and light chains with human vj region and mouse light chain constant region
DK14172437.7T DK2786657T3 (da) 2001-02-16 2002-02-15 Fremgangsmåde til fremstilling af et antistof, som omfatter en variabel human-region og en konstant gnaver-region
DK10010741.6T DK2264163T3 (da) 2001-02-16 2002-02-15 Fremgangsmåder til modifikation af eukaryotiske celler

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK16171559.4T DK3085779T3 (da) 2001-02-16 2002-02-15 Fremgangsmåde til modifikation af eukaryotiske celler
DK14172420.3T DK2787075T3 (da) 2001-02-16 2002-02-15 Gnaver, der er i stand til at producere hybride antistoffer indeholdende variable områder fra mennesker og konstante områder fra gnavere
DK14163642.3T DK2767588T3 (da) 2001-02-16 2002-02-15 Anvendelse af mus, der producerer hybride antistoffer indeholdende humane variable områder og konstante områder fra musen som en kilde til DNA, der koder for et humant, variabelt område af antistoffet

Country Status (19)

Country Link
US (21) US6596541B2 (da)
EP (9) EP3085780B2 (da)
JP (7) JP4412900B2 (da)
AU (1) AU2002244023B2 (da)
CA (1) CA2438390C (da)
CY (8) CY1113964T1 (da)
CZ (1) CZ305619B6 (da)
DE (6) DE14163642T1 (da)
DK (9) DK3626819T3 (da)
ES (8) ES2391391T5 (da)
HK (4) HK1057058A1 (da)
HU (1) HU231221B1 (da)
MX (2) MXPA03007325A (da)
NZ (1) NZ527629A (da)
PL (1) PL217086B1 (da)
PT (8) PT2767588T (da)
TR (2) TR201907641T4 (da)
WO (1) WO2002066630A1 (da)
ZA (1) ZA200306275B (da)

Families Citing this family (986)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908744B1 (en) * 2000-03-14 2005-06-21 Regeneron Pharmaceuticals, Inc. Methods of stimulating cartilage formation
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
DK1461442T3 (da) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgene dyr med humane Ig lambda let kæde gener
JP2006506317A (ja) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド 治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
EP1474522B1 (en) * 2002-01-18 2012-03-07 Morphotek, Inc. A method for generating engineered cells for locus specific gene regulation and analysis
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
US20040128703A1 (en) * 2002-09-09 2004-07-01 Hiroaki Shizuya Methods and compositions for the generation of humanized mice
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
GB2408980B (en) * 2003-12-09 2006-06-07 Nat Biolog Standards Board Genetic reference materials
JP2008512987A (ja) 2004-07-22 2008-05-01 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子
AU2007235496B2 (en) * 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CN102585002A (zh) * 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
US8323815B2 (en) * 2006-06-16 2012-12-04 Porous Power Technology, LLC Optimized microporous structure of electrochemical cells
KR101474227B1 (ko) 2006-10-02 2014-12-18 리제너론 파아마슈티컬스, 인크. 사람 ｉｌ-4 수용체에 대한 고친화성 사람 항체
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
SI2125894T1 (sl) 2007-03-22 2019-05-31 Biogen Ma Inc. Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
PT2336329E (pt) 2007-06-01 2012-12-24 Omt Inc Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
WO2009097006A2 (en) * 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
EP2572729A3 (en) 2007-08-10 2013-06-05 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
GB0718029D0 (en) * 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CA2708776A1 (en) * 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
WO2009103082A2 (en) * 2008-02-17 2009-08-20 Porous Power Technologies, Llc Lamination configurations for battery applications using pvdf highly porous film
US20090223155A1 (en) * 2008-03-05 2009-09-10 Bernard Perry Building Construction Applications for Porous Material
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
US20090227163A1 (en) * 2008-03-05 2009-09-10 Bernard Perry Protective Apparel with Porous Material Layer
US20090226683A1 (en) * 2008-03-05 2009-09-10 Bernard Perry Porous Material Uses in Furniture
US20090222995A1 (en) * 2008-03-05 2009-09-10 Bernard Perry Bedding Applications for Porous Material
BRPI0906261A2 (pt) * 2008-03-31 2015-07-07 Genentech Inc "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
US20100122358A1 (en) * 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
US20090328240A1 (en) * 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
AU2014203150C1 (en) * 2008-06-27 2018-10-18 Merus N.V. Antibody producing non-human mammals
PT3456190T (pt) * 2008-06-27 2022-02-15 Merus Nv Animal murino transgénico produtor de anticorpo
NZ592308A (en) 2008-09-30 2012-11-30 Ablexis Llc Non-human mammals for the production of chimeric antibodies
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
CN112680475A (zh) 2008-12-18 2021-04-20 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
US20100178567A1 (en) * 2008-12-24 2010-07-15 Porous Power Technologies, Llc Mat Forming Spacers in Microporous Membrane Matrix
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
EP2476129B1 (en) 2009-05-20 2019-11-20 Samsung Electronics Co., Ltd. Treatment and adhesive for microporous membranes
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
JP2012531212A (ja) 2009-07-03 2012-12-10 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法
WO2011158009A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) * 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
BR112012000536A2 (pt) * 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
EP3056082B1 (en) 2009-10-06 2018-09-05 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
LT2954779T (lt) * 2009-12-10 2019-05-27 Regeneron Pharmaceuticals, Inc. Pelės, gaminančios sunkiosios grandinės antikūnus
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
EP2516457B9 (en) 2009-12-21 2021-09-29 Regeneron Pharmaceuticals, Inc. Humanized fc gamma r mice
EP2516462B1 (en) 2009-12-23 2015-05-06 Avipep Pty Ltd Immuno-conjugates and methods for producing them
US20130185821A1 (en) * 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) * 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
AR080795A1 (es) 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
NZ601171A (en) 2010-03-31 2014-11-28 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
CA2797271C (en) 2010-04-28 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CN103097523B (zh) 2010-04-29 2016-09-28 Atyr医药公司 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN105820252B (zh) 2010-05-03 2020-07-21 Atyr 医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP5976638B2 (ja) 2010-05-03 2016-08-23 エータイアー ファーマ， インコーポレイテッド アルギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248101B2 (en) 2010-05-04 2016-10-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
ES2727738T3 (es) 2010-06-11 2019-10-18 Regeneron Pharma Producción de animales hembra xy fértiles a partir de células es xy
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
BR112012027995A2 (pt) 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
SI2480675T1 (sl) 2010-06-22 2016-08-31 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo
CN103097418A (zh) 2010-07-09 2013-05-08 霍夫曼-拉罗奇有限公司 抗神经毡蛋白抗体及使用方法
CN103118695B (zh) 2010-07-12 2016-08-03 Atyr医药公司 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2012018610A2 (en) 2010-07-26 2012-02-09 Trianni, Inc. Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
NZ606824A (en) * 2010-08-02 2015-05-29 Regeneron Pharma Mice that make binding proteins comprising vl domains
CN103153341B (zh) 2010-08-03 2015-05-27 霍夫曼-拉罗奇有限公司 慢性淋巴细胞性白血病(cll)生物标志物
BR112013002532A2 (pt) 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
MX2013001336A (es) 2010-08-13 2013-03-08 Roche Glycart Ag Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
CA2806021C (en) 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
KR20130100125A (ko) 2010-08-13 2013-09-09 제넨테크, 인크. 질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체
EP2608801B1 (en) 2010-08-25 2019-08-21 aTyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
WO2012031027A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
EP2635674A4 (en) 2010-11-05 2014-11-05 Transbio Ltd MARKERS FOR ENDOTHELIAL STORAGE CELLS AND USES THEREOF
TW201300417A (zh) 2010-11-10 2013-01-01 Genentech Inc 用於神經疾病免疫療法之方法及組合物
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
NZ609493A (en) 2010-12-16 2015-11-27 Genentech Inc Diagnosis and treatments relating to th2 inhibition
EA028744B1 (ru) 2010-12-20 2017-12-29 Дженентек, Инк. Антитела против мезотелина и иммуноконъюгаты
US20120195910A1 (en) 2010-12-22 2012-08-02 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
WO2012093068A1 (en) 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
PL2663579T3 (pl) 2011-01-14 2017-09-29 The Regents Of The University Of California Przeciwciała terapeutyczne przeciwko białku receptorowemu ror 1 oraz sposoby ich stosowania
EP2650016A1 (en) 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
DK2668212T3 (da) 2011-01-28 2018-07-02 Saonofi Biotechnology Humane antistoffer mod pcsk9 til anvendelse i fremgangsmåder til behandling af bestemte grupper af personer
BR112013020086B1 (pt) 2011-02-08 2020-12-08 Medimmune, Llc Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina
CN105861553B (zh) 2011-02-15 2020-08-14 再生元制药公司 人源化m-csf小鼠
HUE024534T2 (hu) 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
US9624294B2 (en) 2011-03-14 2017-04-18 Cellmid Limited Antibody recognizing N-domain of midkine
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
TW201249867A (en) 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody
RU2013143358A (ru) 2011-04-07 2015-05-20 Дженентек, Инк. Анти-fgfr4 антитела и способы их применения
AU2012245073B2 (en) 2011-04-21 2016-02-11 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
EP2631654B1 (en) 2011-05-12 2015-04-15 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
DK2710035T3 (da) 2011-05-16 2017-06-19 Hoffmann La Roche FGFR1-agonister og fremgangsmåder til anvendelse
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US9193793B2 (en) 2011-06-13 2015-11-24 Csl Limited Antibodies against G-CSFR and uses thereof
BR112013032235A2 (pt) 2011-06-15 2016-11-22 Hoffmann La Roche anticorpos do receptor de epo anti-humano e métodos de uso
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
CA2840221A1 (en) 2011-07-05 2013-01-10 Bioasis Technologies Inc. P97-antibody conjugates and methods of use
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
IL297371A (en) * 2011-08-05 2022-12-01 Regeneron Pharma Humanized mice possess a universal light chain
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
AU2012293161B2 (en) 2011-08-11 2017-04-27 Astellas Pharma Inc. Novel anti-human NGF antibody
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
KR20140068877A (ko) 2011-08-17 2014-06-09 제넨테크, 인크. 불응성 종양에서의 혈관신생의 억제
AU2012299195B9 (en) 2011-08-19 2018-05-10 Regeneron Pharmaceuticals, Inc Anti-Tie2 antibodies uses thereof
KR101723273B1 (ko) 2011-08-23 2017-04-04 로슈 글리카트 아게 2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
KR101681818B1 (ko) 2011-08-23 2016-12-01 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
WO2013026832A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Anti-mcsp antibodies
CN103930781A (zh) 2011-09-15 2014-07-16 霍夫曼-拉罗奇有限公司 促进分化的方法
AU2012308797B2 (en) 2011-09-16 2017-06-01 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9)
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
MX2014002990A (es) 2011-09-19 2014-05-21 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
JP6532678B2 (ja) 2011-10-14 2019-06-19 ジェネンテック， インコーポレイテッド 抗ＨｔｒＡ１抗体及び使用方法
CA2850836A1 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
HUE057680T2 (hu) * 2011-10-17 2022-06-28 Regeneron Pharma Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
GB2496375A (en) * 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
KR102321909B1 (ko) * 2011-10-28 2021-11-05 리제너론 파아마슈티컬스, 인크. 유전자 변형된 ｔ 세포 수용체 마우스
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
HUE048511T2 (hu) 2011-10-28 2020-07-28 Regeneron Pharma Kiméra fõ hisztokompatibilitási komplex (MHC) II molekulákat expresszáló, genetikailag módosított egerek
JP6251682B2 (ja) 2011-10-28 2017-12-20 ジェネンテック， インコーポレイテッド メラノーマ治療の治療の組み合わせ及び方法
WO2013063391A2 (en) 2011-10-28 2013-05-02 Trianni, Inc. Transgenic animals and methods of use
EP2771351B1 (en) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1 epitopes and methods for using same
RS59082B1 (sr) 2011-10-28 2019-09-30 Regeneron Pharma Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti
US20130129718A1 (en) 2011-11-21 2013-05-23 Genentech, Inc. Purification of anti-c-met antibodies
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
ES2930215T3 (es) 2011-12-22 2022-12-07 Hoffmann La Roche Combinaciones de elementos de vector de expresión, procedimientos de generación de células de producción novedosos y su uso para la producción recombinante de polipéptidos
SG11201403445YA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Full length antibody display system for eukaryotic cells and its use
TW201333034A (zh) 2011-12-22 2013-08-16 Astellas Pharma Inc 新穎抗人類ｃｔｇｆ抗體
RU2628703C2 (ru) 2011-12-22 2017-08-21 Ф. Хоффманн-Ля Рош Аг Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
CN104066449B (zh) 2012-01-18 2018-04-27 霍夫曼-拉罗奇有限公司 抗lrp5抗体及使用方法
US20130183294A1 (en) 2012-01-18 2013-07-18 Genentech, Inc. Methods of using fgf19 modulators
EP3912465A1 (en) 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
AU2013216753B2 (en) 2012-02-11 2017-09-21 Genentech, Inc. R-spondin translocations and methods using the same
JP6152120B2 (ja) 2012-02-15 2017-06-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体に基づくアフィニティークロマトグラフィー
DK2814514T3 (da) 2012-02-16 2017-12-18 Atyr Pharma Inc Histidyl-tRNA-synthetaser til behandling af autoimmune og inflammatoriske sygdomme
ES2701064T3 (es) 2012-02-28 2019-02-20 Astellas Pharma Inc Novedoso anticuerpo antirreceptor IL-23 humano
NZ714516A (en) 2012-03-02 2017-06-30 Regeneron Pharma Human antibodies to clostridium difficile toxins
KR20140136462A (ko) 2012-03-06 2014-11-28 리제너론 파마슈티칼스 인코포레이티드 공통 경쇄 마우스
HUE045445T2 (hu) 2012-03-13 2019-12-30 Hoffmann La Roche Kombinált terápia petefészekrák kezelésére
KR20140134672A (ko) 2012-03-16 2014-11-24 리제너론 파마슈티칼스 인코포레이티드 pH-의존성 결합 특성을 나타내는 항원-결합 단백질을 생성하는 마우스
NZ629077A (en) 2012-03-16 2015-12-24 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
HUE037659T2 (hu) 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
WO2013144567A1 (en) 2012-03-28 2013-10-03 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
JP6272299B2 (ja) 2012-04-20 2018-01-31 メルス ナムローゼ フェンノートシャップ Ｉｇ様分子を生産する方法、Ｉｇ様分子の混合物、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物
DK2847335T3 (da) * 2012-04-25 2018-08-13 Regeneron Pharma Nukleasemedieret målretning med store målretningsvektorer
WO2013165940A1 (en) 2012-05-01 2013-11-07 Genentech, Inc. Anti-pmel17 antibodies and immunoconjugates
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
CN104335047B (zh) 2012-05-23 2017-08-15 弗·哈夫曼-拉罗切有限公司 治疗剂的选择方法
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
SG11201407644UA (en) * 2012-06-05 2014-12-30 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
EP3912464A1 (en) * 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
CN104364266A (zh) 2012-06-15 2015-02-18 霍夫曼-拉罗奇有限公司 抗-pcsk9抗体,制剂,剂量给药,和使用方法
CA2871112C (en) 2012-07-04 2020-05-12 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
JP6324376B2 (ja) 2012-07-04 2018-05-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗テオフィリン抗体および使用方法
BR112014030844A2 (pt) 2012-07-04 2019-10-15 Hoffmann La Roche anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
KR20150030693A (ko) 2012-07-05 2015-03-20 제넨테크, 인크. 발현 및 분비 시스템
TR201802376T4 (tr) 2012-07-09 2018-03-21 Genentech Inc Anti-CD79b antikorları içeren immünokonjugatlar.
EP2869851A1 (en) 2012-07-09 2015-05-13 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
CN104540526A (zh) 2012-07-09 2015-04-22 基因泰克公司 包含抗cd79b抗体的免疫偶联物
SG11201500087VA (en) 2012-07-09 2015-02-27 Genentech Inc Immunoconjugates comprising anti-cd22 antibodies
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
KR101774121B1 (ko) 2012-07-13 2017-09-01 로슈 글리카트 아게 이중특이적 항-vegf/항-ang-2 항체 및 안 혈관 질환의 치료에 있어서 이의 용도
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
KR20180011356A (ko) 2012-08-07 2018-01-31 제넨테크, 인크. 교모세포종의 치료를 위한 조합 요법
PT4011915T (pt) 2012-08-21 2024-01-02 Regeneron Pharma Métodos para o tratamento ou prevenção da asma através da administração de um antagonista de il-4r
EP2887959B1 (en) 2012-08-23 2018-12-19 Agensys, Inc. Antibody drug conjugates (adc) that bind to 158p1d7 proteins
MX362456B (es) 2012-08-24 2019-01-18 Univ California Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
EP2703008A1 (en) 2012-08-31 2014-03-05 Sanofi Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
EP2703009A1 (en) 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
EP2706070A1 (en) 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
EP3354663A1 (en) 2012-09-07 2018-08-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
KR102473555B1 (ko) 2012-09-07 2022-12-05 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
CA2879768A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
EP2906681B1 (en) * 2012-10-12 2019-01-09 GlaxoSmithKline Biologicals S.A. Methods of host cell modification
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
KR102402806B1 (ko) 2012-11-05 2022-05-30 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
HUE049012T2 (hu) 2012-11-06 2020-09-28 Medimmune Llc Antitestek S. aureus felszíni determinánsok ellen
EP2917243B1 (en) 2012-11-08 2018-03-14 F.Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
EP3461501A1 (en) 2012-11-13 2019-04-03 F. Hoffmann-La Roche AG Anti-hemagglutinin antibodies and methods of use
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
PT3653049T (pt) 2012-12-14 2023-11-14 Omniab Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
EP3939614A1 (en) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP2953452A1 (en) 2013-02-06 2015-12-16 Regeneron Pharmaceuticals, Inc. B cell lineage based immunogen design with humanized animals
WO2014121325A1 (en) 2013-02-07 2014-08-14 Csl Limited Il-11r binding proteins and uses thereof
PT2840892T (pt) * 2013-02-20 2018-07-20 Regeneron Pharma Animais não humanos com sequências da cadeia pesada da imunoglobulina modificada
EP3561050B1 (en) 2013-02-20 2021-12-08 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
SI2958938T1 (sl) 2013-02-20 2019-08-30 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo humanizirane koreceptorje za celice T
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CA2900097A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
ES2949029T3 (es) 2013-02-22 2023-09-25 Regeneron Pharma Células murinas que expresan complejo mayor de histocompatibilidad humanizado
CA2896259A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Anti-mcsp antibodies
CA2902263A1 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
ES2948808T3 (es) * 2013-03-11 2023-09-19 Regeneron Pharma Ratones transgénicos que expresan moléculas del complejo mayor de histocompatibilidad (CMH) de clase II quiméricas
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
KR20150126863A (ko) 2013-03-13 2015-11-13 리제너론 파마슈티칼스 인코포레이티드 공통 경쇄 마우스
PL2967013T3 (pl) 2013-03-13 2019-07-31 Regeneron Pharmaceuticals, Inc. Mysz, w której zachodzi ekspresja ograniczonego repertuaru lekkiego łańcucha immunoglobuliny
PE20151672A1 (es) 2013-03-14 2015-11-27 Genentech Inc Anticuerpos e inmunoconjugados anti-b7-h4
EP2967012B1 (en) 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
KR20150129718A (ko) 2013-03-14 2015-11-20 리제너론 파아마슈티컬스, 인크. Ｇｒｅｍ 1에 대한 인간 항체
BR112015022576A2 (pt) 2013-03-14 2017-10-24 Genentech Inc produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
JP2016517441A (ja) 2013-03-15 2016-06-16 ジェネンテック， インコーポレイテッド 抗ＣＲＴｈ２抗体及び使用方法
WO2014144292A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
MX2015012872A (es) 2013-03-15 2016-02-03 Ac Immune Sa Anticuerpos anti-tau y metodos de uso.
MY183572A (en) 2013-03-15 2021-02-26 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
SG11201507333XA (en) 2013-03-15 2015-10-29 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
MA38495A1 (fr) 2013-03-15 2017-08-31 Genentech Inc Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
ES2888250T3 (es) 2013-04-16 2022-01-03 Regeneron Pharma Modificación direccionada del genoma de rata
EP3878866A1 (en) 2013-04-29 2021-09-15 F. Hoffmann-La Roche AG Fc-receptor binding modified asymmetric antibodies and methods of use
EA201501063A1 (ru) 2013-04-29 2016-05-31 Ф. Хоффманн-Ля Рош Аг СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2016528168A (ja) 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合が無効となった抗ＩＧＦ−１Ｒ抗体及び血管性眼疾患の処置におけるそれらの使用
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) * 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US20140331339A1 (en) * 2013-05-03 2014-11-06 Kymab Limited Transgenic Non-Human Assay Vertebrates, Assays and Kits
SG10202003997UA (en) 2013-05-20 2020-06-29 Genentech Inc Anti-transferrin receptor antibodies and methods of use
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
EP2810955A1 (en) 2013-06-07 2014-12-10 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP2862877A1 (en) 2013-10-18 2015-04-22 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP3004171B1 (en) 2013-06-07 2021-10-13 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
RS59354B1 (sr) 2013-06-21 2019-10-31 Sanofi Biotechnology Postupci lečenja nosne polipoze davanjem il-4r antagonista
EP3027220A1 (en) 2013-08-01 2016-06-08 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
CN112715485A (zh) 2013-08-07 2021-04-30 瑞泽恩制药公司 缺乏lincRNA的非人类动物
RS58696B1 (sr) 2013-08-09 2019-06-28 Astellas Pharma Inc Novo antitelo protiv humanog tslp receptora
CA2922113C (en) 2013-08-23 2023-05-23 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
EA038192B1 (ru) 2013-08-26 2021-07-21 Регенерон Фармасьютикалз, Инк. Фармацевтические композиции, содержащие диастереомеры макролида, способы их синтезирования и терапевтическое применение
EP3038657A2 (en) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
JP6332773B2 (ja) 2013-09-02 2018-05-30 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 薬物と細胞結合分子との共役のための新規細胞毒性分子
WO2015042108A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
EP3988649A1 (en) * 2013-09-18 2022-04-27 Kymab Limited Methods, cells and organisms
PL3046412T3 (pl) 2013-09-18 2019-11-29 Regeneron Pharma Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane zwierzęta inne niż człowiek do ich wytwarzania
CN105683365A (zh) 2013-10-01 2016-06-15 科马布有限公司 动物模型及治疗分子
JP6846931B2 (ja) 2013-10-11 2021-03-24 サノフィ・バイオテクノロジー 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用
JP2016537965A (ja) 2013-10-11 2016-12-08 ジェネンテック， インコーポレイテッド Ｎｓｐ４阻害剤及び使用方法
KR20160070136A (ko) 2013-10-18 2016-06-17 제넨테크, 인크. 항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
JP6715767B2 (ja) 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
HUE058272T2 (hu) 2013-11-06 2022-07-28 Janssen Biotech Inc Anti-CCL17 antitestek
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
PT3071597T (pt) 2013-11-21 2020-10-08 Hoffmann La Roche Anticorpos anti-alfa-sinucleína e métodos de utilização
EP3460063B1 (en) 2013-12-11 2024-03-13 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
SG10201700961TA (en) 2013-12-11 2017-04-27 Regeneron Pharma Methods and compositions for the targeted modification of a genome
MA39095A1 (fr) 2013-12-13 2018-08-31 Genentech Inc Anticorps et immunoconjugués anti-cd33
SI3083689T1 (sl) 2013-12-17 2020-10-30 Genentech, Inc. Anti-CD3 protitelesa in načini uporabe
JP2017501157A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
JP2017507900A (ja) 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
EP3527587A1 (en) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
WO2015098813A1 (ja) 2013-12-24 2015-07-02 アステラス製薬株式会社 新規抗ヒトｂｄｃａ－２抗体
CN105899540B (zh) 2014-01-03 2020-02-07 豪夫迈·罗氏有限公司 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及它们作为血脑屏障穿梭物的应用
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
KR102278979B1 (ko) 2014-01-03 2021-07-19 에프. 호프만-라 로슈 아게 공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도
KR20160107190A (ko) 2014-01-15 2016-09-13 에프. 호프만-라 로슈 아게 변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
WO2015112909A1 (en) 2014-01-24 2015-07-30 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
ES2764973T3 (es) 2014-02-03 2020-06-05 Bioasis Technologies Inc Proteínas de fusión de P97
KR20210121288A (ko) 2014-02-08 2021-10-07 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
BR112016018205A8 (pt) 2014-02-08 2018-04-17 Genentech Inc métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
TW201902515A (zh) 2014-02-12 2019-01-16 美商建南德克公司 抗jagged1抗體及使用方法
US20150231236A1 (en) 2014-02-14 2015-08-20 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
US10392605B2 (en) 2014-02-19 2019-08-27 Bioasis Technologies Inc. P97-IDS fusion proteins
UA117608C2 (uk) 2014-02-21 2018-08-27 Дженентек, Інк. Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
EP3973987B1 (en) 2014-02-21 2024-01-10 Sanofi Biotechnology Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
EP3122757B1 (en) 2014-02-28 2023-09-06 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
MA39746A (fr) 2014-03-14 2021-04-28 Hoffmann La Roche Compositions de sécrétion de polypeptides hétérologues et procédés associés
CN114558129A (zh) 2014-03-17 2022-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
CA2941514A1 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
DK3126394T3 (da) 2014-03-31 2020-01-13 Hoffmann La Roche Anti-OX40-antistoffer og fremgangsmåder til anvendelse
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
CN106164288A (zh) 2014-04-02 2016-11-23 豪夫迈·罗氏有限公司 检测多特异性抗体轻链错配的方法
AU2015240595B2 (en) 2014-04-03 2020-02-27 Igm Biosciences, Inc. Modified J-chain
BR112016024319B1 (pt) 2014-04-18 2024-01-23 Acceleron Pharma Inc USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
EP3137610B1 (en) 2014-05-01 2019-03-06 Bioasis Technologies, Inc. P97-polynucleotide conjugates
MY179927A (en) 2014-05-19 2020-11-19 Regeneron Pharma Genetically modified non-human animals expressing human epo
CA2946662A1 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
MX2020004803A (es) * 2014-05-30 2021-10-13 Regeneron Pharma Animales con dipeptidil peptidasa iv (dpp4) humanizada.
MX2016016133A (es) * 2014-06-06 2017-08-04 Regeneron Pharma Métodos y composiciones para modificar un locus dirigido.
EP3155015A1 (en) 2014-06-11 2017-04-19 F. Hoffmann-La Roche AG Anti-lgr5 antibodies and uses thereof
AU2015274277B2 (en) 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CA2953499C (en) 2014-06-23 2023-10-24 Regeneron Pharmaceuticals, Inc. Nuclease-mediated dna assembly
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
HUE041584T2 (hu) 2014-06-26 2019-05-28 Regeneron Pharma Célzott genetikai módosítások és alkalmazási módszerek és készítmények
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
EP3166966A1 (en) 2014-07-10 2017-05-17 Affiris AG Substances and methods for the use in prevention and/or treatment in huntington's disease
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
EP3169801A1 (en) 2014-07-14 2017-05-24 F. Hoffmann-La Roche AG Diagnostic methods and compositions for treatment of glioblastoma
CA2955294A1 (en) 2014-07-16 2016-01-21 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
CN107106678A (zh) 2014-07-16 2017-08-29 赛诺菲生物技术公司 用于治疗患有高胆固醇血症的高心血管风险患者的方法
AU2015301491A1 (en) 2014-08-15 2017-02-02 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
SI3191135T1 (sl) 2014-09-12 2021-01-29 Genentech, Inc. Anti-HER2 protitelesa in imunokonjugati
PE20170670A1 (es) 2014-09-12 2017-06-06 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US9657099B2 (en) 2014-09-16 2017-05-23 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies
WO2016044396A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
AU2015317370A1 (en) 2014-09-19 2017-03-23 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
US9840557B2 (en) 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
LT3262071T (lt) 2014-09-23 2020-06-25 F. Hoffmann-La Roche Ag Anti-cd79b imunokonjugatų naudojimo būdai
BR112017007770A2 (pt) 2014-10-15 2018-01-16 Regeneron Pharma cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
CN107074938A (zh) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
WO2016070001A1 (en) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
BR112017009151A2 (pt) 2014-11-03 2018-03-06 Genentech, Inc. ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
AU2015343339A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
SG11201703376QA (en) 2014-11-06 2017-05-30 Genentech Inc Combination therapy comprising ox40 binding agonists and tigit inhibitors
RU2714116C2 (ru) 2014-11-06 2020-02-11 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМ СВЯЗЫВАНИЕМ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AR102522A1 (es) 2014-11-06 2017-03-08 Hoffmann La Roche Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a
EP3552488A1 (en) 2014-11-10 2019-10-16 F. Hoffmann-La Roche AG Animal model for nephropathy and agents for treating the same
TWI705976B (zh) 2014-11-10 2020-10-01 美商建南德克公司 抗介白素-33抗體及其用途
EP3875481A1 (en) 2014-11-14 2021-09-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
WO2016077666A1 (en) 2014-11-14 2016-05-19 Regeneron Pharmaceuticals, Inc. Method for generating high affinity antibodies
CN107206073A (zh) 2014-11-14 2017-09-26 赛诺菲生物技术公司 通过施用il‑4r拮抗剂用于治疗伴随鼻息肉的慢性鼻窦炎的方法
RU2017121096A (ru) 2014-11-17 2018-12-19 Дженентек, Инк. Комбинированная терапия, включающая применение ох40-связывающих агонистов и антагонистов связывания оси pd-1
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
BR112017010324A2 (pt) 2014-11-20 2018-05-15 F. Hoffmann-La Roche Ag método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
AU2015349692B2 (en) 2014-11-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide RNAs
ES2844000T3 (es) 2014-11-24 2021-07-21 Regeneron Pharma Animales no humanos que expresan el complejo CD3 humanizado
JP6554280B2 (ja) * 2014-11-28 2019-07-31 株式会社デンソーテン データ処理装置、画像処理方法、及び、プログラム
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
AR102918A1 (es) 2014-12-05 2017-04-05 Genentech Inc Anticuerpos anti-cd79b y métodos de uso
WO2016094566A2 (en) 2014-12-10 2016-06-16 Genentech, Inc. Blood brain barrier receptor antibodies and methods of use
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
BR112017013104A2 (pt) 2014-12-19 2018-05-15 Regeneron Pharma métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano.
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
JP6970017B2 (ja) 2015-02-09 2021-11-24 メモリアル スローン ケタリング キャンサー センター ヒトａ３３抗原とｄｏｔａ金属複合体に親和性を有する多重特異性抗体及びその使用
EP3256491A1 (en) 2015-02-13 2017-12-20 bioMmune Technologies Inc. Antibodies to l-type voltage gated channels and related methods
RU2739617C2 (ru) 2015-03-09 2020-12-28 Эдженсис, Инк. Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками flt3
WO2016149276A1 (en) 2015-03-16 2016-09-22 Genentech, Inc. Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
CN107690279B (zh) 2015-03-16 2021-07-02 瑞泽恩制药公司 非人动物表现出上运动神经元功能和下运动神经元功能以及感知减弱
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
PL3271389T3 (pl) 2015-03-20 2020-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizujące przeciwciała wiążące się z gp120 i ich stosowanie
PL3273992T3 (pl) 2015-03-23 2020-11-16 Jounce Therapeutics, Inc. Przeciwciała przeciwko icos
WO2016160615A1 (en) 2015-03-27 2016-10-06 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
EP3828199A1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Alk7: actriib heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
RS62546B1 (sr) 2015-04-07 2021-12-31 Alector Llc Antitela protiv sortilina i postupci za njihovu upotrebu
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
FI3282835T3 (fi) 2015-04-13 2023-07-20 Regeneron Pharma Humanisoituja sirpa-il15-poistogeenisiä hiiriä ja niiden käyttömenetelmiä
WO2016172551A2 (en) 2015-04-24 2016-10-27 Genentech, Inc. Methods of identifying bacteria comprising binding polypeptides
EP3778640A1 (en) 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
CN107592812A (zh) 2015-05-11 2018-01-16 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
HUE051815T2 (hu) 2015-05-12 2021-03-29 Hoffmann La Roche Terápiás és diagnosztikai eljárások rákra
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
CN107771182A (zh) 2015-05-29 2018-03-06 豪夫迈·罗氏有限公司 人源化抗埃博拉病毒糖蛋白抗体和使用方法
WO2016196185A1 (en) 2015-05-29 2016-12-08 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a c9orf72 locus
CA2984003A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN107810012A (zh) 2015-06-02 2018-03-16 豪夫迈·罗氏有限公司 使用抗il‑34抗体治疗神经疾病的组合物和方法
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
TWI827405B (zh) 2015-06-05 2023-12-21 美商建南德克公司 抗-ｔａｕ抗體及使用方法
KR20180011839A (ko) 2015-06-08 2018-02-02 제넨테크, 인크. 항-ox40 항체를 이용한 암의 치료 방법
WO2016200835A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
US11136390B2 (en) 2015-06-12 2021-10-05 Alector Llc Anti-CD33 antibodies and methods of use thereof
US10017577B2 (en) 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
WO2016205200A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
KR20180023952A (ko) 2015-06-16 2018-03-07 제넨테크, 인크. FcRH5에 대한 인간화 및 친화도 성숙 항체 및 사용방법
AU2016280070B2 (en) 2015-06-17 2022-09-15 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
MX2017016169A (es) 2015-06-17 2018-08-15 Genentech Inc Anticuerpos anti-her2 y metodos de uso.
DK3313879T3 (da) 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrinreceptor-antistoffer med tilpasset affinitet
US20170029520A1 (en) 2015-06-29 2017-02-02 Genentech, Inc. Compositions and methods for use in organ transplantation
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP7320350B2 (ja) 2015-08-04 2023-08-03 アクセルロン ファーマ インコーポレイテッド 骨髄増殖性障害を処置するための方法
CN114605549A (zh) 2015-08-05 2022-06-10 詹森生物科技公司 抗cd154抗体及其使用方法
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
WO2017035241A1 (en) 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
CN113372443A (zh) 2015-09-18 2021-09-10 中外制药株式会社 Il-8-结合抗体及其应用
MY191756A (en) 2015-09-23 2022-07-14 Genentech Inc Optimized variants of anti-vegf antibodies
RU2757135C2 (ru) 2015-09-24 2021-10-11 АБВИТРО ЭлЭлСи Композиции антител к вич и способы их применения
CN113956358A (zh) 2015-09-25 2022-01-21 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
WO2017059387A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
MY196646A (en) 2015-09-30 2023-04-27 Janssen Biotech Inc Agonistic Antibodies Specifically Binding Human CD40 And Methods of use
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
KR20180054864A (ko) 2015-10-02 2018-05-24 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
EP3356404B1 (en) 2015-10-02 2021-08-18 F. Hoffmann-La Roche AG Anti-pd1 antibodies and methods of use
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
AU2016342269A1 (en) 2015-10-22 2018-03-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
RS61871B1 (sr) 2015-10-30 2021-06-30 Hoffmann La Roche Anti-htra1 antitela i postupci za njihovu primenu
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
MX2018005550A (es) 2015-11-03 2019-07-18 Janssen Biotech Inc Anticuerpos que se unen especificamente a tim-3 y sus usos.
EP3371217A1 (en) 2015-11-08 2018-09-12 H. Hoffnabb-La Roche Ag Methods of screening for multispecific antibodies
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
BR112018003984A2 (pt) 2015-12-09 2018-09-25 Hoffmann La Roche anticorpos
US20180355043A1 (en) 2015-12-17 2018-12-13 Janssen Biotech, Inc. Antibodies Specifically Binding HLA-DR and Their Uses
PE20240365A1 (es) 2015-12-18 2024-03-04 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y metodos de uso
EP3400246B1 (en) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
KR20230006929A (ko) 2016-01-13 2023-01-11 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
EP3405489A1 (en) 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
EA039072B9 (ru) 2016-01-25 2022-02-04 Регенерон Фармасьютикалз, Инк. Производные майтанзиноида, их конъюгаты и способы применения
EP3411476B1 (en) 2016-02-04 2024-04-24 Trianni, Inc. Enhanced production of immunoglobulins
MA44242A (fr) * 2016-02-16 2018-12-26 Regeneron Pharma Animaux non humains ayant un gène de kynuréninase mutant
EP4234013A3 (en) 2016-02-17 2023-11-08 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
MX2018010361A (es) 2016-02-29 2019-07-08 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
EP3423157A1 (en) 2016-03-03 2019-01-09 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
TWI759287B (zh) 2016-03-15 2022-04-01 日商中外製藥股份有限公司 使用ｐｄ－１軸結合拮抗劑和抗ｇｐｃ３抗體治療癌症的方法
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
AU2017242028A1 (en) 2016-03-29 2018-09-06 Regeneron Pharmaceuticals, Inc. Genetic variant-phenotype analysis system and methods of use
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
KR20180132843A (ko) 2016-04-08 2018-12-12 리제너론 파아마슈티컬스, 인크. Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법
EP3865511A1 (en) 2016-04-14 2021-08-18 F. Hoffmann-La Roche AG Anti-rspo3 antibodies and methods of use
CN109154613A (zh) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 用于监测和治疗癌症的方法
EP3443120A2 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
KR20190003679A (ko) 2016-04-28 2019-01-09 리제너론 파아마슈티컬스, 인크. 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법
EP3889175A1 (en) 2016-05-02 2021-10-06 F. Hoffmann-La Roche AG The contorsbody - a single chain target binder
CN109071640B (zh) 2016-05-11 2022-10-18 豪夫迈·罗氏有限公司 经修饰抗生腱蛋白抗体及使用方法
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
AU2017268458B2 (en) 2016-05-20 2022-07-21 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide RNAS
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CA3059010A1 (en) 2016-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
KR102598120B1 (ko) 2016-06-03 2023-11-07 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
BR112018074771A2 (pt) 2016-06-06 2019-03-06 F. Hoffmann-La Roche Ag proteínas de fusão para oftalmologia com retenção aumentada nos olhos
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
KR102534895B1 (ko) 2016-06-14 2023-05-24 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
CN116143918A (zh) 2016-06-24 2023-05-23 豪夫迈·罗氏有限公司 抗聚泛素多特异性抗体
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
CN109415435B (zh) 2016-07-04 2024-01-16 豪夫迈·罗氏有限公司 新型抗体形式
EP3496739B1 (en) 2016-07-15 2021-04-28 Acceleron Pharma Inc. Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP7264580B2 (ja) 2016-07-27 2023-04-25 アクセルロン ファーマ インコーポレイテッド 骨髄線維症を処置するための方法および組成物
BR112019001179A2 (pt) 2016-07-29 2019-04-30 Chugai Seiyaku Kabushiki Kaisha anticorpo biespecífico que exibe atividade alternativa aumentada de função de cofator fviii
ES2965134T3 (es) 2016-07-29 2024-04-11 Regeneron Pharma Ratones que contienen mutaciones que resultan en la expresión de fibrilina-1 truncada en C
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
EP3282019A1 (en) 2016-08-09 2018-02-14 Medizinische Universität Wien Genotyping and treatment of cancer, in particular chronic lymphocytic leukemia
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
SG11201900746RA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
KR102554331B1 (ko) 2016-08-12 2023-07-10 얀센 바이오테크 인코포레이티드 향상된 효능적 활성을 갖는 Fc 조작된 항-TNFR 수퍼패밀리 구성원 항체 및 그의 사용 방법
MA46046A (fr) 2016-08-29 2019-07-03 Regeneron Pharma Anticorps anti-gremlin-1 (grem1) et procédés d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP6976315B2 (ja) 2016-09-19 2021-12-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 補体因子に基づくアフィニティークロマトグラフィー
JP7051826B2 (ja) 2016-09-23 2022-04-11 シーエスエル、リミテッド 凝固因子結合タンパク質及びその使用
RU2752785C2 (ru) 2016-09-23 2021-08-04 Дженентек, Инк. Применение антагонистов il-13 для лечения атопического дерматита
JP7026678B2 (ja) 2016-09-30 2022-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ９ｏｒｆ７２座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物
US11976111B2 (en) 2016-10-05 2024-05-07 Acceleron Pharma Inc. ActRIIa and ALK4 polypeptides for treating kidney fibrosis, inflammation and injury
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
JP2019535237A (ja) 2016-10-06 2019-12-12 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
AU2017345786A1 (en) 2016-10-21 2019-05-23 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
IL293585B2 (en) 2016-10-21 2023-11-01 Adimab Llc Respiratory syncytial virus antibodies and methods for their production and use
WO2018075954A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CN110267678A (zh) 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 抗mic抗体和使用方法
CN109906272A (zh) * 2016-10-31 2019-06-18 国立大学法人鸟取大学 产生人抗体的非人动物和使用该非人动物的人抗体制作方法
LT3535298T (lt) 2016-11-02 2021-12-27 Jounce Therapeutics, Inc. Antikūnai prieš pd-1 ir jų panaudojimas
CA3038720A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
SG10202104259RA (en) 2016-11-08 2021-06-29 Regeneron Pharma Steroids and protein-conjugates thereof
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CN110036029A (zh) 2016-11-17 2019-07-19 瑞泽恩制药公司 用抗angptl8抗体处理肥胖的方法
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
EP3548082B1 (en) 2016-11-29 2024-05-15 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for averting opioid addiction
US10876009B2 (en) 2016-11-30 2020-12-29 Croda International Plc Aqueous binder system, a coating composition and a coating
JP7193457B2 (ja) 2016-12-07 2022-12-20 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
BR112019011988A2 (pt) 2016-12-13 2019-11-05 Astellas Pharma Inc anticorpo anti-cd73 humana
KR102390246B1 (ko) 2016-12-21 2022-04-22 에프. 호프만-라 로슈 아게 항체의 시험관내 글리코조작에 있어서의 효소의 재사용
WO2018114877A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag In vitro glycoengineering of antibodies
CA3045970A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
EP3558347A1 (en) 2016-12-22 2019-10-30 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
US11464216B2 (en) 2016-12-27 2022-10-11 National University Corporation Gunma University Production method for conditional knockout animal
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
RU2021133626A (ru) 2017-01-23 2022-01-31 Регенерон Фармасьютикалз, Инк. Варианты hsd17b13 и их применения
US10713373B2 (en) * 2017-02-09 2020-07-14 Lifesite, Inc. Computing system with information storage mechanism and method of operation thereof
US11021535B2 (en) 2017-02-10 2021-06-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
KR102362006B1 (ko) 2017-02-10 2022-02-14 제넨테크, 인크. 항-트립타제 항체, 이의 조성물, 및 그의 용도
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
ES2953595T3 (es) 2017-03-01 2023-11-14 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
WO2018175752A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
MA49289A (fr) 2017-04-03 2020-02-12 Hoffmann La Roche Anticorps se liant à steap-1
WO2018184964A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
WO2018184965A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
TWI707871B (zh) 2017-04-05 2020-10-21 瑞士商赫孚孟拉羅股份公司 抗lag3抗體
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
US20190078160A1 (en) 2017-04-21 2019-03-14 Genentech, Inc. Use of klk5 antagonists for treatment of a disease
CA3059468A1 (en) 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
CN111094335B (zh) 2017-05-15 2022-08-23 罗切斯特大学 广泛中和的抗流感单克隆抗体及其用途
US11491237B2 (en) 2017-05-18 2022-11-08 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
WO2018222854A1 (en) 2017-06-01 2018-12-06 Regeneron Pharmaceuticals, Inc. Human antibodies to bet v 1 and methods of use thereof
JP7235733B2 (ja) 2017-06-05 2023-03-08 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ－１に特異的に結合する抗体、及び使用方法
KR20200014379A (ko) 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
KR20200022467A (ko) 2017-06-28 2020-03-03 리제너론 파아마슈티컬스, 인크. 항-인간 유두종 바이러스 (hpv) 항원-결합 단백질 및 그의 사용 방법
US11674962B2 (en) 2017-07-21 2023-06-13 Genentech, Inc. Therapeutic and diagnostic methods for cancer
AU2018302343B2 (en) 2017-07-21 2020-11-26 Trianni, Inc. Single chain vh and heavy chain antibodies
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
CA3070796A1 (en) 2017-07-24 2019-01-31 Regeneron Pharmaceuticals, Inc. Anti-cd8 antibodies and uses thereof
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
KR20200033798A (ko) 2017-08-03 2020-03-30 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
US11021540B2 (en) 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
MA50667A (fr) 2017-09-29 2020-08-05 Chugai Pharmaceutical Co Ltd Molécule multispécifique de liaison à l'antigène ayant une activité de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molécule en tant que principe actif
JP2021500865A (ja) 2017-09-29 2021-01-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． スタフィロコッカス（Ｓｔａｐｈｓｙｌｏｃｏｃｃｕｓ）標的抗原および補体成分に結合する二重特異性抗原結合分子ならびにその使用
EP3476942B1 (en) 2017-10-27 2022-01-26 Trianni, Inc. Long germline dh genes and long hcdr3 antibodies
WO2019089473A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
JP2021500930A (ja) 2017-11-01 2021-01-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｏｍｐボディ−多価標的結合物質
CA3079129C (en) 2017-11-01 2023-02-28 F. Hoffmann-La Roche Ag Trifab-contorsbody
TW201923089A (zh) 2017-11-06 2019-06-16 美商建南德克公司 癌症之診斷及治療方法
WO2019108662A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use
PT3720279T (pt) 2017-12-05 2022-10-06 Regeneron Pharma Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos
US11365265B2 (en) 2017-12-13 2022-06-21 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
US11977081B2 (en) 2017-12-18 2024-05-07 Regeneron Pharmaceuticals, Inc. ANGPTL8 assay and uses thereof
BR112020011469A2 (pt) 2017-12-21 2020-11-24 F. Hoffmann-La Roche Ag anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
MX2020006668A (es) 2017-12-22 2020-10-07 Jounce Therapeutics Inc Anticuerpos para lilrb2.
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
CN111699198B (zh) 2017-12-28 2023-09-05 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
CN111542543B (zh) 2017-12-28 2023-12-22 南京传奇生物科技有限公司 针对pd-l1的抗体及其变体
JP2021508498A (ja) 2017-12-29 2021-03-11 アレクター リミテッド ライアビリティ カンパニー 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
WO2019136487A2 (en) 2018-01-08 2019-07-11 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
US20200339686A1 (en) 2018-01-16 2020-10-29 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
US20190225689A1 (en) 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
KR20200115576A (ko) 2018-01-26 2020-10-07 리제너론 파아마슈티컬스, 인크. 항-tmprss2 항체 및 항원-결합 단편
MX2020007772A (es) 2018-01-26 2020-09-18 Regeneron Pharma Anticuerpos humanos contra hemaglutinina de influenza.
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
US11866498B2 (en) 2018-02-08 2024-01-09 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
KR102417088B1 (ko) 2018-02-09 2022-07-07 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
AU2019225249A1 (en) 2018-02-26 2020-09-17 Genentech, Inc. Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
KR20200129127A (ko) 2018-03-06 2020-11-17 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 심혈관 위험을 감소시키기 위한 pcsk9 억제제의 용도
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CN116874591A (zh) 2018-03-24 2023-10-13 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途
US11747340B2 (en) 2018-03-24 2023-09-05 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying HLA-associated tumor peptides
SG11202008620VA (en) 2018-03-26 2020-10-29 Regeneron Pharma Humanized rodents for testing therapeutic agents
JP7382950B2 (ja) 2018-03-26 2023-11-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ＰｆＲＨ５抗体およびその抗原結合断片
AU2019245243A1 (en) 2018-03-29 2020-09-03 Genentech, Inc Modulating lactogenic activity in mammalian cells
KR20200138720A (ko) 2018-03-30 2020-12-10 난징 레전드 바이오테크 씨오., 엘티디. Lag-3에 대한 단일-도메인 항체 및 이의 용도
WO2019192432A1 (zh) 2018-04-02 2019-10-10 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
US11958895B2 (en) 2018-05-03 2024-04-16 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
CR20200563A (es) 2018-05-24 2021-05-11 Janssen Biotech Inc Agentes aglutinantes de psma y usos de estos
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
JP2021524249A (ja) 2018-05-24 2021-09-13 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３抗体及びその使用
BR112020023844A2 (pt) 2018-05-25 2021-04-13 Alector Llc Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica
WO2019232246A1 (en) 2018-05-31 2019-12-05 Glyconex Inc. Therapeutic antibodies binding to biantennary lewis b and lewis y antigens
KR20210022616A (ko) 2018-06-01 2021-03-03 리제너론 파마슈티칼스 인코포레이티드 희소 벡터 기반 매트릭스 변환 방법 및 시스템
EP4023059A1 (en) 2018-06-14 2022-07-06 Regeneron Pharmaceuticals, Inc. Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
CA3104470A1 (en) 2018-06-19 2019-12-26 Regeneron Pharmaceuticals, Inc. Anti-factor xii/xiia antibodies and uses thereof
MX2020014091A (es) 2018-06-23 2021-05-27 Genentech Inc Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii.
CA3099176A1 (en) 2018-06-29 2020-01-02 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
BR112020026784A2 (pt) 2018-07-10 2021-03-30 Regeneron Pharmaceuticals, Inc. Anticorpo monoclonal de ocorrência não natural, ensaio, e, método para determinar um nível de imunogenicidade de uma terapia de anticorpo monoclonal em um paciente
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
AU2019306217B2 (en) 2018-07-16 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies
EA202190194A1 (ru) 2018-07-17 2021-04-16 Хьюмабс Байомед Са Антитела к видам бактерий рода campylobacter
EP3823611A1 (en) 2018-07-18 2021-05-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
US11155606B2 (en) 2018-07-24 2021-10-26 Medimmune, Llc Antibody directed against S. aureus clumping factor a (ClfA)
AU2019318556A1 (en) 2018-08-10 2021-03-04 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
CN112839960A (zh) 2018-08-10 2021-05-25 中外制药株式会社 抗cd137抗原结合分子及其应用
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
WO2020047029A1 (en) 2018-08-29 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
EA202190235A1 (ru) 2018-08-31 2021-07-02 Алектор Ллс Антитела к cd33 и способы их применения
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
US20220053741A1 (en) 2018-09-13 2022-02-24 Regeneron Pharmaceuticals, Inc. Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy
EP3853611A1 (en) 2018-09-19 2021-07-28 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for bladder cancer
EP4249917A3 (en) 2018-09-21 2023-11-08 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
MX2021004173A (es) 2018-10-09 2021-09-08 Medimmune Llc Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
US20200109200A1 (en) 2018-10-09 2020-04-09 Genentech, Inc. Methods and systems for determining synapse formation
AU2019361983A1 (en) 2018-10-18 2021-05-20 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
JOP20210093A1 (ar) 2018-10-31 2023-01-30 Astellas Pharma Inc جسم مضاد fn14 غير متوافق مع الإنسان
JP2022512860A (ja) 2018-11-06 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
SG11202102060PA (en) 2018-11-21 2021-03-30 Regeneron Pharma Anti-staphylococcus antibodies and uses thereof
AU2018451747A1 (en) 2018-12-06 2021-06-17 F. Hoffmann-La Roche Ag Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
US20220064260A1 (en) 2018-12-14 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
EP3898667A2 (en) 2018-12-20 2021-10-27 F. Hoffmann-La Roche AG Modified antibody fcs and methods of use
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
WO2020132214A2 (en) 2018-12-20 2020-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
WO2020131632A1 (en) 2018-12-20 2020-06-25 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
BR112021010374A2 (pt) 2018-12-21 2021-08-24 23Andme, Inc. Anticorpos anti-il-36 e métodos de uso dos mesmos
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
CN113710702A (zh) 2019-01-14 2021-11-26 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
BR112021014276A2 (pt) 2019-01-22 2021-09-28 Genentech, Inc. Anticorpos iga isolados, moléculas de fusão igg-iga isoladas, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, para tratar um indivíduo, para aumentar a expressão de dímeros, trímeros ou tetrâmeros, para aumentar a produção de polímeros, para aumentar a produção de dímeros, para aumentar a produção de um polímero, para diminuir a produção de polímeros, para aumentar a expressão transitória de um anticorpo, para expressar dímeros de moléculas de fusão, para expressar dímeros, trímeros ou tetrâmeros, para purificar um anticorpo, para purificar um estado oligomérico de um anticorpo, composição farmacêutica e uso do anticorpo
JPWO2020153467A1 (ja) 2019-01-24 2021-12-02 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
EP3917962A1 (en) 2019-02-01 2021-12-08 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins
US20220153819A1 (en) 2019-02-12 2022-05-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
CN117679532A (zh) 2019-02-15 2024-03-12 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
CA3125380A1 (en) * 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
KR20210129083A (ko) 2019-02-22 2021-10-27 리제너론 파마슈티칼스 인코포레이티드 유전적으로 변형된 나트륨 채널을 갖는 설치류 및 이의 사용 방법
AU2020228383A1 (en) 2019-02-27 2021-09-23 Genentech, Inc. Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
CN113543799A (zh) 2019-03-01 2021-10-22 艾洛基治疗公司 靶向dll3的嵌合抗原受体和结合剂
AU2020238811A1 (en) 2019-03-08 2021-07-22 Genentech, Inc. Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
JP2022528414A (ja) 2019-04-04 2022-06-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化凝固因子１２遺伝子座を含む非ヒト動物
CA3133359C (en) 2019-04-04 2023-04-11 Regeneron Pharmaceuticals, Inc. Methods for scarless introduction of targeted modifications into targeting vectors
MX2021012335A (es) 2019-04-10 2021-11-12 Regeneron Pharma Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
AU2020258384A1 (en) 2019-04-15 2021-11-04 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
CA3136888A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
TW202043291A (zh) 2019-04-19 2020-12-01 美商建南德克公司 抗mertk抗體及使用方法
BR112021021349A2 (pt) 2019-04-26 2022-02-01 Allogene Therapeutics Inc Métodos de fabricação de células car t alogênicas
CA3138306A1 (en) 2019-05-01 2020-11-05 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
WO2020226986A2 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
WO2020227228A2 (en) 2019-05-03 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
CA3138045C (en) 2019-05-14 2024-02-20 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
JP2022534867A (ja) 2019-06-04 2022-08-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
JP2022535418A (ja) 2019-06-05 2022-08-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド カッパ遺伝子座から発現される限られたラムダ軽鎖レパートリーを有する非ヒト動物及びその使用
TW202112229A (zh) 2019-06-07 2021-04-01 美商雷傑納榮製藥公司 包含人化白蛋白基因座之非人的動物
TW202112817A (zh) 2019-06-11 2021-04-01 美商阿列克特有限責任公司 抗揀選蛋白抗體之使用方法
MX2021015156A (es) 2019-06-11 2022-01-18 Regeneron Pharma Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
MA56203A (fr) 2019-06-12 2022-04-20 Regeneron Pharma Anticorps humains dirigés contre la protéine morphogénétique osseuse 6
MA56515A (fr) 2019-06-21 2022-04-27 Regeneron Pharma Utilisation de molécules de liaison à l'antigène bispécifiques se liant à psma et cd3 en combinaison avec une co-stimulation de 4-1bb
AU2020294790A1 (en) 2019-06-21 2021-12-16 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
WO2021000067A1 (zh) 2019-06-29 2021-01-07 杭州多禧生物科技有限公司 一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法
EP3993623A1 (en) 2019-07-01 2022-05-11 Trianni, Inc. Transgenic mammals and methods of use thereof
CN114502725A (zh) 2019-07-01 2022-05-13 特里安尼公司 转基因哺乳动物及使用方法
JP2022538139A (ja) 2019-07-02 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
MX2022000649A (es) 2019-07-16 2022-06-08 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r.
CA3147735A1 (en) 2019-07-26 2021-02-04 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
CN114174338A (zh) 2019-07-31 2022-03-11 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
MX2022001156A (es) 2019-07-31 2022-02-22 Hoffmann La Roche Anticuerpos que se fijan a gprc5d.
JP2022542964A (ja) 2019-07-31 2022-10-07 アレクトル エルエルシー 抗ｍｓ４ａ４ａ抗体、及びその使用方法
CA3147113A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
IL289613B2 (en) 2019-08-05 2023-09-01 Regeneron Pharma IL-4R antagonist in combination with a scit regimen to increase immunotherapeutic efficacy and tolerability to a grass-specific allergen
US20210047425A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
JOP20220035A1 (ar) 2019-08-15 2023-01-30 Janssen Biotech Inc مواد وطرق لتحسين أجزاء المتغير أحادي السلسلة
EP3785536B1 (en) 2019-08-28 2022-01-26 Trianni, Inc. Adam6 knockin mice
TW202118512A (zh) 2019-09-12 2021-05-16 美商建南德克公司 治療狼瘡性腎炎之組成物及方法
BR112022004972A2 (pt) 2019-09-18 2022-06-28 Genentech Inc Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
TW202126699A (zh) 2019-09-20 2021-07-16 美商建南德克公司 用於抗類胰蛋白酶抗體之投藥
PE20221110A1 (es) 2019-09-27 2022-07-11 Genentech Inc Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
WO2021059075A1 (en) 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
US20220324962A1 (en) 2019-09-27 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance antibodies and uses thereof
US20220281997A1 (en) 2019-09-27 2022-09-08 Nanjing GenScript Biotech Co., Ltd. Anti-VHH Domain Antibodies and Use Thereof
CA3154710A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
WO2021076196A1 (en) 2019-10-18 2021-04-22 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP4051707A1 (en) 2019-10-28 2022-09-07 Regeneron Pharmaceuticals, Inc. Anti-hemagglutinin antibodies and methods of use thereof
US20220389103A1 (en) 2019-11-06 2022-12-08 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
CA3152314A1 (en) 2019-11-15 2021-05-20 Andrea ALLMENDINGER Prevention of visible particle formation in aqueous protein solutions
US20210222133A1 (en) 2019-11-18 2021-07-22 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2021099600A1 (en) 2019-11-22 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
BR112022010179A2 (pt) 2019-11-25 2022-08-30 Mabloc Llc Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso
AU2020395122A1 (en) 2019-12-02 2022-06-09 Regeneron Pharmaceuticals, Inc. Peptide-MHC II protein constructs and uses thereof
KR20220110553A (ko) 2019-12-06 2022-08-08 사노피 바이오테크놀로지 Il-33 길항제를 투여하여 copd를 치료하는 방법
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
JP2023504204A (ja) 2019-12-09 2023-02-01 サノフィ・バイオテクノロジー デジタル的に識別されたｉｌ－４／ｉｌ－１３関連障害を治療する方法
IL293617A (en) 2019-12-10 2022-08-01 Regeneron Pharma Use of pcsk9 surveillance to treat homozygous hereditary hypercholesterolemia
MX2022007158A (es) 2019-12-13 2022-07-11 Genentech Inc Anticuerpos anti-ly6g6d y metodos de uso.
PE20221326A1 (es) 2019-12-13 2022-09-09 Alector Llc Anticuerpos anti-mertk y metodos de uso de los mismos
JP7296467B2 (ja) 2019-12-18 2023-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｍａｇｅ－ａ４に結合する抗体
WO2021119761A1 (en) 2019-12-20 2021-06-24 Hudson Institute of Medical Research Cxcl10 binding proteins and uses thereof
AU2020415382A1 (en) 2019-12-23 2022-08-18 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing allergic asthma by administering an IL-33 antagonist and/or an IL-4R antagonist
AU2019479791B2 (en) 2019-12-27 2024-05-02 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
MX2022008323A (es) 2020-01-08 2022-08-08 Regeneron Pharma Uso de aminoácidos para mejorar la señal en análisis del espectro de masas.
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021151031A1 (en) 2020-01-24 2021-07-29 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
IL294861A (en) 2020-01-27 2022-09-01 Regeneron Pharma Multiplexed quantification of protein post-translational modifications using tandem mass labeling
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
JP2023511626A (ja) 2020-01-28 2023-03-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｐｎｐｌａ３遺伝子座を含む非ヒト動物および使用方法
US11598756B2 (en) 2020-01-30 2023-03-07 Regeneron Pharmaceuticals, Inc. Platform for native liquid chromatography-mass spectrometry
KR20220134585A (ko) 2020-01-31 2022-10-05 리제너론 파아마슈티컬스, 인크. 액체 크로마토그래피-질량 분석법에 의한 고 신뢰성 화합물 식별
AU2021212197A1 (en) 2020-01-31 2022-08-04 BioNTech SE Methods of inducing neoepitope-specific T cells with a PD-1 axis binding antagonist and an RNA vaccine
BR112022015374A2 (pt) 2020-02-03 2022-10-11 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
CA3108168A1 (en) 2020-02-05 2021-08-05 Yue Zhang Conjugates of cell-binding molecules with cytotoxic agents
WO2021158883A1 (en) 2020-02-07 2021-08-12 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use
MX2022009476A (es) 2020-02-10 2022-08-22 Regeneron Pharma Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
JP2023513400A (ja) 2020-02-10 2023-03-30 上海詩健生物科技有限公司 Ｃｌｄｎ１８．２抗体及びその使用
AU2021218927A1 (en) 2020-02-10 2022-09-22 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
US11945872B2 (en) 2020-02-11 2024-04-02 Regeneron Pharmaceuticals, Inc. Anti-ACVR1 antibodies and uses thereof
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
TW202140012A (zh) 2020-02-12 2021-11-01 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
ES2954629T3 (es) 2020-02-26 2023-11-23 Vir Biotechnology Inc Anticuerpos contra SARS-CoV-2
KR20220145859A (ko) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
KR20220148209A (ko) 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물 및 그 용도
AU2021235564A1 (en) 2020-03-13 2022-11-03 Janssen Biotech, Inc. Materials and methods for binding Siglec-3/CD33
CR20220461A (es) 2020-03-13 2022-10-21 Genentech Inc Anticuerpos anti-interleucina-33 y usos de estos
IL296427A (en) 2020-03-19 2022-11-01 Genentech Inc Isoform-selective anti-tgf antibodies and methods of use
EP4125348A1 (en) 2020-03-23 2023-02-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
CN115867649A (zh) 2020-03-24 2023-03-28 基因泰克公司 Tie2结合剂及其使用方法
JP2023518841A (ja) 2020-03-26 2023-05-08 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質が減少した修飾哺乳動物細胞
AU2021244266A1 (en) 2020-03-27 2022-12-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist
WO2021202590A1 (en) 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof
JP2023519930A (ja) 2020-04-01 2023-05-15 ユニバーシティ オブ ロチェスター インフルエンザｈ３ｎ２ウイルスのヘマグルチニン（ｈａ）およびノイラミニダーゼ（ｎａ）に対するモノクローナル抗体
MY197648A (en) 2020-04-02 2023-06-30 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
EP4127724A1 (en) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
CN115461620A (zh) 2020-04-14 2022-12-09 瑞泽恩制药公司 通过正交偏最小二乘法对色谱性能进行紫外线监测
CN116194476A (zh) 2020-04-14 2023-05-30 维尔生物科技有限公司 针对sars-cov-2的抗体和其使用方法
WO2021209402A2 (en) 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugates
WO2021211984A1 (en) 2020-04-16 2021-10-21 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
CA3175530A1 (en) 2020-04-24 2021-10-28 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
CA3178472A1 (en) 2020-04-24 2021-10-28 F. Hoffmann-La Roche Ag Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
JP2023523450A (ja) 2020-04-28 2023-06-05 ジェネンテック， インコーポレイテッド 非小細胞肺がん免疫療法のための方法及び組成物
MX2021015024A (es) 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
TW202200212A (zh) 2020-05-03 2022-01-01 中國大陸商聯寧（蘇州）生物製藥有限公司 包含抗-trop-2抗體之抗體藥物結合物
KR20230010676A (ko) 2020-05-08 2023-01-19 비르 바이오테크놀로지, 인코포레이티드 Sars-cov-2에 대한 항체
CN115916335A (zh) 2020-05-12 2023-04-04 瑞泽恩制药公司 抗glp1r拮抗剂抗体及其使用方法
EP4149558A1 (en) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
WO2021228917A1 (en) 2020-05-15 2021-11-18 F. Hoffmann-La Roche Ag Prevention of visible particle formation in parenteral protein solutions
WO2021233853A1 (en) 2020-05-19 2021-11-25 F. Hoffmann-La Roche Ag The use of chelators for the prevention of visible particle formation in parenteral protein solutions
KR20230015965A (ko) 2020-05-22 2023-01-31 리제너론 파아마슈티컬스, 인크. Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
BR112022024149A2 (pt) 2020-05-26 2023-02-07 Regeneron Pharma Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno
TW202210510A (zh) 2020-05-27 2022-03-16 美商健生生物科技公司 包含ｃｄ３抗原結合域之蛋白質及其用途
EP4157461A1 (en) 2020-05-29 2023-04-05 23Andme, Inc. Anti-cd200r1 antibodies and methods of use thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
MX2022015376A (es) 2020-06-02 2023-04-14 Dynamicure Biotechnology Llc Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
TW202204396A (zh) 2020-06-08 2022-02-01 瑞士商赫孚孟拉羅股份公司 抗hbv抗體及使用方法
RU2751237C1 (ru) * 2020-06-10 2021-07-12 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
EP4165415A1 (en) 2020-06-12 2023-04-19 Genentech, Inc. Methods and compositions for cancer immunotherapy
BR112022025229A2 (pt) 2020-06-12 2023-03-07 Vir Biotechnology Inc Terapias de anticorpos para infecção por sars-cov-2
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
IL299103A (en) 2020-06-18 2023-02-01 Regeneron Pharma Formulations of activin A antibody and methods of its use
IL298946A (en) 2020-06-18 2023-02-01 Genentech Inc Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
WO2021259880A1 (en) 2020-06-22 2021-12-30 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
CA3184747A1 (en) 2020-06-24 2021-12-30 Genentech, Inc. Apoptosis resistant cell lines
WO2021261620A1 (ko) 2020-06-25 2021-12-30 주식회사 휴맵 이형접합성 형질전환 동물
JP2023531968A (ja) 2020-07-01 2023-07-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｂｅｔ ｖ １抗体を使用してアレルギーを治療する方法
CN116133689A (zh) 2020-07-07 2023-05-16 豪夫迈·罗氏有限公司 作为治疗性蛋白质制剂的稳定剂的替代表面活性剂
JP2023534437A (ja) 2020-07-13 2023-08-09 リジェネロン ファーマシューティカルズ，インク． タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用
TW202216780A (zh) 2020-07-17 2022-05-01 美商建南德克公司 抗ｎｏｔｃｈ２抗體及其使用方法
CA3188649A1 (en) 2020-07-21 2022-01-27 Genentech, Inc. Antibody-conjugated chemical inducers of degradation of brm and methods thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AU2021317111A1 (en) 2020-07-29 2023-03-30 Janssen Biotech, Inc. Proteins comprising HLA-G antigen binding domains and their uses
IL300121A (en) 2020-07-29 2023-03-01 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CN116096365A (zh) 2020-08-07 2023-05-09 瑞泽恩制药公司 涉及angptl3抑制剂的治疗难治性高胆固醇血症的方法
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
EP4204449A1 (en) 2020-08-26 2023-07-05 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
WO2022047222A2 (en) 2020-08-28 2022-03-03 Genentech, Inc. Crispr/cas9 multiplex knockout of host cell proteins
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
AU2021341526A1 (en) 2020-09-14 2023-04-27 Ichnos Sciences SA Antibodies that bind to il1rap and uses thereof
WO2022056494A1 (en) 2020-09-14 2022-03-17 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
WO2022067269A2 (en) 2020-09-28 2022-03-31 Humabs Biomed Sa Antibodies against sars-cov-2
EP4225443A1 (en) 2020-10-05 2023-08-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20220169739A1 (en) 2020-10-05 2022-06-02 Sanofi Biotechnology Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
WO2022075793A1 (ko) 2020-10-08 2022-04-14 주식회사 휴맵 인간화 면역글로불린 유전자좌를 포함하는 게놈을 가지는 형질전환 비인간-동물 제조방법
CA3198590A1 (en) 2020-10-13 2022-04-21 Rajkumar Ganesan Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
WO2022081718A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
JP2023548034A (ja) 2020-10-22 2023-11-15 ヤンセン バイオテツク，インコーポレーテツド デルタ様リガンド３（ｄｌｌ３）抗原結合ドメインを含むタンパク質及びその使用
IL301702A (en) 2020-10-22 2023-05-01 Regeneron Pharma Anti-FGFR2 antibodies and methods of using them
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
AU2021374594A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
CN116635071A (zh) 2020-11-16 2023-08-22 安斯泰来制药株式会社 抗tspan8-抗cd3双特异性抗体和抗tspan8抗体
EP4244248A1 (en) 2020-11-16 2023-09-20 F. Hoffmann-La Roche AG Fab high mannose glycoforms
TW202229329A (zh) 2020-11-23 2022-08-01 美商維爾生物科技股份有限公司 針對流感神經胺酸酶的廣泛中和抗體
EP4247844A1 (en) 2020-11-23 2023-09-27 VIR Biotechnology, Inc. Antibodies against influenza a viruses
JP2023551667A (ja) 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド 抗－インフルエンザ抗体及びその組合せ
TW202235107A (zh) 2020-11-25 2022-09-16 美商維爾生物科技股份有限公司 結合至多種乙型冠狀病毒的抗體
AU2021392039A1 (en) 2020-12-02 2023-06-29 Alector Llc Methods of use of anti-sortilin antibodies
IL303529A (en) 2020-12-09 2023-08-01 Trianni Inc Heavy chain antibodies only
US20240065239A1 (en) 2020-12-16 2024-02-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
JP7326584B2 (ja) 2020-12-17 2023-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｈｌａ－ｇ抗体及びその使用
US20220195058A1 (en) 2020-12-18 2022-06-23 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to npr1 agonists
US20220196671A1 (en) 2020-12-20 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods for Identification of Scrambled Disulfides in Biomolecules
CN116635413A (zh) 2020-12-23 2023-08-22 再生元制药公司 用于获得结合跨膜蛋白的抗体的方法和生产所述抗体的细胞
AU2021410655A1 (en) 2020-12-23 2023-06-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
US20220220211A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
CN116802298A (zh) 2021-01-13 2023-09-22 安斯泰来制药株式会社 与ActRIIA、ActRIIB和Fn14结合的多特异性抗体
EP4277926A1 (en) 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
WO2022159842A1 (en) 2021-01-25 2022-07-28 Vir Biotechnology, Inc. Antibody combination therapies for sars-cov-2 infection
MX2023008691A (es) 2021-01-25 2023-08-01 Regeneron Pharmaceuticals Inc Anticuerpos anti- pdgf-b y metodos de su uso para tratar la hipertension arterial pulmonar (pah).
KR20230137393A (ko) 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
EP4291226A1 (en) 2021-02-09 2023-12-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Antibodies targeting the spike protein of coronaviruses
EP4291306A1 (en) 2021-02-09 2023-12-20 University of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
CN117136197A (zh) 2021-02-09 2023-11-28 胡默波斯生物医学公司 抗呼吸道合胞病毒、人偏肺病毒和小鼠肺炎病毒的抗体和其使用方法
CN117440832A (zh) 2021-03-03 2024-01-23 索伦托药业有限公司 包括抗bcma抗体的抗体-药物缀合物
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
US20240141048A1 (en) 2021-03-05 2024-05-02 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
AR125074A1 (es) 2021-03-12 2023-06-07 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
CA3213599A1 (en) 2021-03-15 2022-09-22 Genentech, Inc. Compositions and methods of treating lupus nephritis
CN116981696A (zh) 2021-03-18 2023-10-31 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
JP2024511610A (ja) 2021-03-23 2024-03-14 アレクトル エルエルシー コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
US20230040715A1 (en) 2021-03-24 2023-02-09 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
JP2024512035A (ja) 2021-03-24 2024-03-18 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ２２及びｃｄ７９ｂを標的とする抗体
JP2024511424A (ja) 2021-03-25 2024-03-13 ダイナミキュア バイオテクノロジー エルエルシー 抗ｉｇｆｂｐ７構築物およびその使用
AR125255A1 (es) 2021-04-02 2023-06-28 Regeneron Pharma Métodos de predicción y modulación de la glicación de una proteína
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
EP4324848A1 (en) 2021-04-16 2024-02-21 Korea University Research and Business Foundation Human antibody targeting covid-19 virus
JP2024514222A (ja) 2021-04-19 2024-03-28 ジェネンテック， インコーポレイテッド 改変された哺乳動物細胞
CA3212049A1 (en) 2021-04-20 2022-10-27 Susan D. Croll Human antibodies to artemin and methods of use thereof
EP4327823A1 (en) 2021-04-22 2024-02-28 Astellas Pharma Inc. Anti-cldn4/anti-cd137 bispecific antibody
IL307821A (en) 2021-04-30 2023-12-01 Hoffmann La Roche Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4334353A1 (en) 2021-05-04 2024-03-13 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
EP4333613A1 (en) 2021-05-05 2024-03-13 Trianni, Inc. Transgenic rodents expressing chimeric equine-rodent antibodies and methods of use thereof
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
AU2022273063A1 (en) 2021-05-12 2023-11-23 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
KR20240010469A (ko) 2021-05-21 2024-01-23 제넨테크, 인크. 관심 재조합 생성물의 생성을 위한 변형된 세포
CA3218489A1 (en) 2021-05-24 2022-12-01 Vir Biotechnology, Inc. Engineered polypeptides
CN113278071B (zh) 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
CN117480184A (zh) 2021-06-04 2024-01-30 中外制药株式会社 抗ddr2抗体及其用途
TW202313045A (zh) 2021-06-09 2023-04-01 瑞士商赫孚孟拉羅股份公司 用於癌症治療之組合療法
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
EP4355786A1 (en) 2021-06-16 2024-04-24 Alector LLC Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
IL308959A (en) 2021-06-18 2024-01-01 Nammi Therapeutics Inc Fusion protein composition(s) containing masked type I interferons (IFNalpha and IFNbeta) for use in cancer therapy and methods thereof
IL308633A (en) 2021-06-25 2024-01-01 Chugai Pharmaceutical Co Ltd Use of anti-CTLA-4 antibodies
CA3221833A1 (en) 2021-06-25 2022-12-29 Chugai Seiyaku Kabushiki Kaisha Anti-ctla-4 antibody
CA3226042A1 (en) 2021-07-05 2023-01-12 Regeneron Pharmaceuticals, Inc. Utilization of antibodies to shape antibody responses to an antigen
US20230125469A1 (en) 2021-07-14 2023-04-27 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
PE20240638A1 (es) 2021-07-14 2024-03-27 Genentech Inc Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso
KR20240036570A (ko) 2021-07-22 2024-03-20 에프. 호프만-라 로슈 아게 이종이량체 Fc 도메인 항체
WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof
US20230146317A1 (en) 2021-07-26 2023-05-11 Sanofi Biotechnology Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
IL307947A (en) 2021-07-28 2023-12-01 Regeneron Pharma An antiviral compound of proteins
CN117794953A (zh) 2021-08-03 2024-03-29 豪夫迈·罗氏有限公司 双特异性抗体及使用方法
CN117897409A (zh) 2021-08-13 2024-04-16 基因泰克公司 抗类胰蛋白酶抗体的给药
WO2023028468A1 (en) 2021-08-23 2023-03-02 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
TW202325727A (zh) 2021-08-30 2023-07-01 美商建南德克公司 抗聚泛素多特異性抗體
CA3230613A1 (en) 2021-09-01 2023-03-09 Daren J. AUSTIN Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
WO2023039442A1 (en) 2021-09-08 2023-03-16 Vir Biotechnology, Inc. Broadly neutralizing antibody combination therapies for sars-cov-2 infection
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
AU2022357559A1 (en) 2021-10-01 2024-05-02 Abcellera Biologics Inc. Transgenic rodents for cell line identification and enrichment
JPWO2023058723A1 (da) 2021-10-08 2023-04-13
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
AU2022362681A1 (en) 2021-10-14 2024-04-04 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
US20230183362A1 (en) 2021-10-20 2023-06-15 Sanofi Biotechnology Methods for treating prurigo nodularis by administering an il-4r antagonist
US20230131338A1 (en) 2021-10-22 2023-04-27 Regeneron Pharmaceuticals, Inc. Factor xi a2 domain-binding antibodies and methods of use thereof
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
CA3235395A1 (en) 2021-11-10 2023-05-19 Peter Burrows Transgenic mammals and methods of use thereof
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
AU2022389969A1 (en) 2021-11-16 2024-05-02 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
WO2023092052A1 (en) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023089587A1 (en) 2021-11-22 2023-05-25 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
US20230250170A1 (en) 2021-12-06 2023-08-10 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof
WO2023108047A1 (en) 2021-12-08 2023-06-15 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
US20230220089A1 (en) 2021-12-30 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
WO2023137443A1 (en) 2022-01-14 2023-07-20 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof
US20230322958A1 (en) 2022-01-19 2023-10-12 Genentech, Inc. Anti-Notch2 Antibodies and Conjugates and Methods of Use
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
TW202332767A (zh) 2022-02-02 2023-08-16 美商雷傑納榮製藥公司 用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ***
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
WO2023152581A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Method of treating cancer with psmaxcd3 antibody
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
US20230257432A1 (en) 2022-02-11 2023-08-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for screening 4r tau targeting agents
TW202337497A (zh) 2022-02-18 2023-10-01 中國大陸商重慶明道浩悅生物科技有限公司 鼻內調配物及抗sars-cov-2棘蛋白抗體
WO2023173026A1 (en) 2022-03-10 2023-09-14 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
JP2024517042A (ja) 2022-04-13 2024-04-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の薬学的組成物及び使用方法
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist
WO2023215737A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
WO2023230445A2 (en) 2022-05-23 2023-11-30 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
US20240034798A1 (en) 2022-07-08 2024-02-01 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r antagonist
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20240102045A1 (en) 2022-07-19 2024-03-28 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024026411A1 (en) 2022-07-27 2024-02-01 Humabs Biomed Sa Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
US20240052051A1 (en) 2022-07-29 2024-02-15 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
WO2024047021A1 (en) 2022-08-29 2024-03-07 Sanofi Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024073606A1 (en) 2022-09-28 2024-04-04 Regeneron Pharmaceuticals, Inc. Antibody resistant modified receptors to enhance cell-based therapies
WO2024073679A1 (en) 2022-09-29 2024-04-04 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
WO2024077239A1 (en) 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
WO2024092133A1 (en) 2022-10-27 2024-05-02 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5350689A (en) 1987-05-20 1994-09-27 Ciba-Geigy Corporation Zea mays plants and transgenic Zea mays plants regenerated from protoplasts or protoplast-derived cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH07509137A (ja) * 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
US5436149A (en) 1993-02-19 1995-07-25 Barnes; Wayne M. Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension
CA2161351C (en) * 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6096878A (en) 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5508189A (en) 1994-04-26 1996-04-16 Pepperdine University Regeneration of plants from cultured guard cell protoplasts
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6069010A (en) * 1995-09-11 2000-05-30 Axys Pharmaceuticals, Inc. High throughput gene inactivation with large scale gene targeting
US5928914A (en) 1996-06-14 1999-07-27 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Methods and compositions for transforming cells
US5763715A (en) 1996-10-08 1998-06-09 Stone & Webster Engineering Corp. Butadiene removal system for ethylene plants with front end hydrogenation systems
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6075859A (en) 1997-03-11 2000-06-13 Qualcomm Incorporated Method and apparatus for encrypting data in a wireless communication system
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
ES2250105T3 (es) 1999-02-05 2006-04-16 Therapeutic Human Polyclonals, Inc. Anticuerpos policlonales humanos de animales transgenicos no humanos.
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6355412B1 (en) 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
WO2001019394A2 (en) 1999-09-15 2001-03-22 Therapeutic Human Polyclonals, Inc. Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
GB2356897B (en) 1999-12-01 2003-05-14 Secr Defence Improved nozzle
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1461442T3 (da) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgene dyr med humane Ig lambda let kæde gener
AU2003230741A1 (en) 2002-03-22 2003-10-13 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
US20030182675A1 (en) 2002-03-22 2003-09-25 Origen Therapeutics Functional disruption of avian immunoglobulin genes
WO2004072115A2 (en) 2003-02-05 2004-08-26 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies
ES2473596T3 (es) 2003-07-15 2014-07-07 Therapeutic Human Polyclonals, Inc. Loci de inmunoglobulina humanizada
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
US7618403B2 (en) 2004-05-14 2009-11-17 Mcneil-Ppc, Inc. Fluid management device with fluid transport element for use within a body
RU2394839C2 (ru) 2004-12-21 2010-07-20 Астразенека Аб Антитела против ангиопоэтина-2 и их применение
EP1871383B1 (en) * 2005-04-04 2017-11-15 Intersect ENT, Inc. Device and methods for treating paranasal sinus conditions
KR101232139B1 (ko) 2005-12-13 2013-02-12 엘지디스플레이 주식회사 액정 표시 장치
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
KR101474227B1 (ko) 2006-10-02 2014-12-18 리제너론 파아마슈티컬스, 인크. 사람 ｉｌ-4 수용체에 대한 고친화성 사람 항체
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CN101809037B (zh) 2007-07-31 2014-01-15 瑞泽恩制药公司 人cd20的人抗体及其使用方法
EP2572729A3 (en) 2007-08-10 2013-06-05 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US8321568B2 (en) 2008-03-31 2012-11-27 Amazon Technologies, Inc. Content management
US8194152B2 (en) 2008-09-05 2012-06-05 CSR Technology, Inc. Image processing under flickering lighting conditions using estimated illumination parameters
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
SI2480675T1 (sl) 2010-06-22 2016-08-31 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo
HUE024534T2 (hu) 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
KR102402806B1 (ko) 2012-11-05 2022-05-30 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
SG10201700961TA (en) 2013-12-11 2017-04-27 Regeneron Pharma Methods and compositions for the targeted modification of a genome
AU2015349692B2 (en) 2014-11-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide RNAs

Also Published As

Publication number Publication date
EP1360287A4 (en) 2004-04-14
HK1146298A1 (en) 2011-05-20
HK1198259A1 (en) 2015-03-20
CZ305619B6 (cs) 2016-01-13
TR201802443T4 (tr) 2018-03-21
DK3085780T3 (da) 2019-10-07
ES2608362T5 (es) 2024-03-27
JP2009240331A (ja) 2009-10-22
PT3626819T (pt) 2021-05-25
US9388446B2 (en) 2016-07-12
HUP0303187A2 (hu) 2003-12-29
US20160316731A1 (en) 2016-11-03
ES2725712T5 (es) 2023-10-31
JP2014176391A (ja) 2014-09-25
US6596541B2 (en) 2003-07-22
PT2787075T (pt) 2017-01-03
EP1360287A1 (en) 2003-11-12
PT3085780T (pt) 2019-09-30
EP2264163A2 (en) 2010-12-22
US9371553B2 (en) 2016-06-21
JP5805056B2 (ja) 2015-11-04
JP6426670B2 (ja) 2018-11-21
CZ20032192A3 (en) 2004-03-17
EP3085780B2 (en) 2023-06-28
HU231221B1 (hu) 2022-01-28
CY1122039T1 (el) 2020-10-14
DK2767588T3 (da) 2020-11-23
US10378037B2 (en) 2019-08-13
JP6402368B2 (ja) 2018-10-10
ES2725712T3 (es) 2019-09-26
CY1122059T1 (el) 2020-11-25
CY1117254T1 (el) 2017-04-26
HUP0303187A3 (en) 2010-01-28
CY1118500T1 (el) 2017-07-12
US20140017229A1 (en) 2014-01-16
EP2787075B2 (en) 2023-10-18
US20140017782A1 (en) 2014-01-16
EP2786657B1 (en) 2018-02-07
NZ527629A (en) 2005-03-24
US20140017781A1 (en) 2014-01-16
ES2660749T3 (es) 2018-03-26
AU2002244023B2 (en) 2007-05-10
CY1124458T1 (el) 2022-07-22
ES2744220T3 (es) 2020-02-24
US20140018522A1 (en) 2014-01-16
EP3572508A1 (en) 2019-11-27
MX343591B (es) 2016-11-11
DE10010741T1 (de) 2014-08-21
US20130210137A1 (en) 2013-08-15
US8502018B2 (en) 2013-08-06
ZA200306275B (en) 2004-08-13
PT2786657T (pt) 2018-04-04
PL364281A1 (en) 2004-12-13
US20040018626A1 (en) 2004-01-29
CY1120265T1 (el) 2019-07-10
US9376699B2 (en) 2016-06-28
EP3085779A1 (en) 2016-10-26
ES2827482T3 (es) 2021-05-21
US9382567B2 (en) 2016-07-05
EP1360287B1 (en) 2012-09-12
EP3626819B1 (en) 2021-03-31
DK1360287T4 (da) 2019-06-11
US20140020124A1 (en) 2014-01-16
DK2264163T3 (da) 2015-10-26
EP2787075A1 (en) 2014-10-08
US20140017238A1 (en) 2014-01-16
EP3626819A1 (en) 2020-03-25
HK1198260A1 (en) 2015-03-20
JP2013090631A (ja) 2013-05-16
US20140041068A1 (en) 2014-02-06
EP2264163B1 (en) 2015-10-14
DK3572508T1 (da) 2019-12-09
EP3085780B1 (en) 2019-06-26
CA2438390A1 (en) 2002-08-29
DK3572508T3 (en) 2022-12-19
JP2016189796A (ja) 2016-11-10
WO2002066630A1 (en) 2002-08-29
DK2787075T3 (da) 2017-02-27
PL217086B1 (pl) 2014-06-30
DE19203913T1 (de) 2020-05-14
US10378039B2 (en) 2019-08-13
JP5345463B2 (ja) 2013-11-20
EP2767588B1 (en) 2020-08-19
EP2786657A3 (en) 2015-03-04
ES2391391T5 (es) 2019-07-19
DK3626819T1 (en) 2020-03-30
EP3085780A1 (en) 2016-10-26
US9528136B2 (en) 2016-12-27
JP2004524841A (ja) 2004-08-19
ES2556767T3 (es) 2016-01-20
US10227625B2 (en) 2019-03-12
US8791323B2 (en) 2014-07-29
ES2608362T3 (es) 2017-04-10
DE14163642T1 (de) 2014-10-09
US9708635B2 (en) 2017-07-18
US20140023637A1 (en) 2014-01-23
US20140020125A1 (en) 2014-01-16
PT1360287E (pt) 2012-12-06
EP3085779B1 (en) 2019-04-03
DK3626819T3 (da) 2021-06-28
MXPA03007325A (es) 2003-12-04
CY1123912T1 (el) 2022-03-24
JP2018108115A (ja) 2018-07-12
US20140073010A1 (en) 2014-03-13
US10378040B2 (en) 2019-08-13
US20130130388A1 (en) 2013-05-23
HK1057058A1 (en) 2004-03-12
ES2869225T3 (es) 2021-10-25
JP4412900B2 (ja) 2010-02-10
US20070061900A1 (en) 2007-03-15
US10640800B2 (en) 2020-05-05
EP2786657A2 (en) 2014-10-08
DK3085779T3 (da) 2019-06-24
EP1360287B2 (en) 2019-04-03
US20110258710A1 (en) 2011-10-20
US20140033336A1 (en) 2014-01-30
ES2391391T3 (es) 2012-11-23
US10526630B2 (en) 2020-01-07
US9353394B2 (en) 2016-05-31
JP2012095670A (ja) 2012-05-24
US10584364B2 (en) 2020-03-10
EP3572508B1 (en) 2022-11-23
CY1113964T1 (el) 2016-07-27
EP3085779B2 (en) 2023-05-31
DK2786657T3 (da) 2018-03-26
PT2767588T (pt) 2020-11-04
EP2264163A3 (en) 2011-07-06
CA2438390C (en) 2014-10-28
DE19172361T1 (de) 2020-01-16
EP2767588A1 (en) 2014-08-20
PT2264163E (pt) 2016-01-08
JP5692863B2 (ja) 2015-04-01
US20140033337A1 (en) 2014-01-30
US20110283376A1 (en) 2011-11-17
EP2787075B1 (en) 2016-11-30
US20020106629A1 (en) 2002-08-08
US10378038B2 (en) 2019-08-13
TR201907641T4 (tr) 2019-06-21
US20140013457A1 (en) 2014-01-09
DE14172420T1 (de) 2014-12-04
DE14172437T1 (de) 2014-11-27
PT3085779T (pt) 2019-05-31

Similar Documents

Publication Publication Date Title
DK1360287T3 (da) Fremgangsmåder til modifikation af eukaryotiske celler
DK1362050T3 (da) Pyrimidinderivater til inhibition af celleproliferation
DK1438306T3 (da) Derivater af UK-2A
DK1148875T3 (da) Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer
DK1235594T3 (da) Inhibering af sekretion fra ikke-neuronale celler
DE60130586D1 (de) Speicherzelle
DK1277722T3 (da) Fremgangsmåde til fremstilling af methanol
DK1417180T3 (da) Fremstilling af aminopyrimidinforbindelser
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
DK1575416T3 (da) Fremgangsmåder til diagnosticering af præeklampsi
DE50111319D1 (de) Selbstnivellierender Baulaser
FR2830516B1 (fr) Suspension de turboreacteur
DK1366144T3 (da) Anordning til fremstilling af celler
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1410012T3 (da) Bestemmelse af graviditetstilstand
DK1563061T3 (da) Dyrkning af hårinducerende celler
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1600441T3 (da) Krystallinsk form af elrcanidipinhydrochlorid til anvendelse som et antihypertensivt middel
DK1407037T3 (da) Fremgangsmåde til fremstilling af tagatose
DK1337228T3 (da) Sammensætninger til fjernelse af human cerumen
ITMI20010954A0 (it) Procedimento di iodurazione
DK1503995T3 (da) Fremgangsmåde til fremstilling af substituerede phenylsulfonylurinstoffer
DK1281707T3 (da) Fremgangsmåde til fremstilling af 5-substituerede isobenzenfuraner
IL162634A0 (en) Uses of an endothelial cell receptor
DK1392711T3 (da) Fremgangsmåde til fremstilling af xylose